Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

The latest outbreak, caused by the Bundibugyo Ebola virus, has so far affected 600 people and has caused 139 suspected deaths, as per the latest update by the World Health Organization (WHO).

Amid increasing testing, sequencing, and clinical trial efforts to tackle the Bundibugyo Ebola virus, a new study indicates a possible new spillover event from wild animals.

The study, led by scientists from the Democratic Republic of the Congo and Uganda, released the first complete genomes of Bundibugyo Ebola virus from the May 2026 outbreak. The initial genomes reveal a new spillover event.

As of now, the index case is a nurse who fell ill on 24 April and died three days later in Bunia, the capital of Ituri province in DR Congo. But she was unlikely to have been infected by a patient, as per experts.

Genomes Suggest Fresh Spillover Event

Scott Pegan, a professor of biomedical sciences at the University of California, Riverside School of Medicine, said that, similar to the Zaire and Sudan viruses, the Bundibugyo Ebola virus is not transmitted through the air.

“The Bundibugyo virus primarily spreads through contact with infected bodily fluids,” he said, adding that “the origin of this outbreak is likely what is considered a spillover event”.

He explained that the Ebola viruses are zoonotic in nature, with their primary hosts considered to be fruit bats.

“Spillover events of human infectious diseases occur when humans encounter infected animal feces or process bushmeat from infected animals,” Pegan said.

Researchers Trace Possible Wildlife Source

“The genomes, posted on a virological website on May 17, display a distinct genetic lineage that does NOT match any previously sequenced Bundibugyo strains, suggesting a recent introduction from an animal reservoir into humans rather than sustained human-to-human transmission,” said Cheng-Yi Lee in a post on social media platform X.

Cheng-Yi added that "phylogenetic analysis shows that the new sequences form a separate cluster, supporting the inference of a fresh zoonotic spillover".

The expert stated that the most plausible source of this spillover is wildlife inhabiting the Ituri forest. He pointed out to "fruit bats or other mammals known to harbor filoviruses, which could have been implicated in earlier outbreaks through hunting or contact with infected animal tissues".

The ecological surveillance ongoing in the region will be essential to identify the exact reservoir and to mitigate the risk of future spillover events, the scientists said.

“Ebola outbreak likely from a new spillover event rather than from previously circulating virus,” added Rajeev Jayadevan, citing the study.

The Co-Chairman of the National IMA COVID Task Force & Past President, Indian Medical Association, Cochin, explained that "the virus jumps to humans from infected animals such as bats, monkeys, and apes, usually through contact with blood, body fluids, excrement, or raw meat during hunting and butchering".

The Risk Of Future Ebola Outbreaks?

Further, Pegan shared that containing the current outbreak of the Bundibugyo virus is critical because "the more the virus interfaces with humans, the greater the chance for it to move from a spillover event to a crossover one".

Symptoms To Watch For

Symptoms of Bundibugyo virus disease are similar to other forms of Ebola and include:

• Fever
• Headache
• Muscle pain
• Weakness
• Diarrhea
• Vomiting
• Stomach pain
• Unexplained bleeding or bruising, usually in later stages of illness.

A US doctor infected with the Ebola virus, while treating patients infected with the deadly disease in Democratic Republic of the Congo has been admitted to Berlin's Charité hospital today.

The German Health Ministry acquiesced to a request from the United States for the patient to be treated in Germany rather than the United States due to the shorter travel time from Uganda and the Charité's experience in dealing with Ebola, Deutsche Welle reported.

The patient was flown to Berlin on a special medical aircraft and was then driven to the hospital in a specially designed vehicle escorted by police. The aircraft also carried six other people with whom the infected man had contact.

The German Health Ministry has reassured the public that there is no danger of the deadly virus spreading to the general population.

The Charité hospital specializes in the treatment of such cases and the patient is being housed in a completely isolated ward, separate from the rest of the clinic, the report said.

The German Health Ministry, however, noted that the mortality rate following modern treatment and specialist monitoring at a clinic like Berlin's Charité drops from around 60 per cent to 20 per cent-30 per cent.

Ebola Cases Rise To Over 130: WHO Considers Use Of Experimental Vaccines

Also read: UK Scientists Begin Drug Trial To Mend Broken Heart Syndrome

Tedros Adhanom Ghebreyesus said there had been at least 500 suspected cases of Ebola and 130 suspected deaths due to the Bundibugyo strain in DR Congo since the new outbreak began in April.

Global health leaders are also considering whether vaccines or medicines still in development could be used to fight Ebola. Dr Mesfin Teklu Tessema, senior director of health at the International Rescue Committee, which works in the DRC’s Ituri Province, where most cases have been reported, told the The Guardian he expected current known cases were “the tip of the iceberg”.

Spread across the porous border to South Sudan, he said, was probably “a matter of when”. He warned that a weak public health infrastructure there meant “we are actually flying blind”.

A WHO official in Ituri province said the outbreak could take a long time to bring under control.

“I don’t think that in two months we will be done with this outbreak,” Anne Ancia, the WHO’s representative for the DRC, told reporters in Geneva at the World Health Assembly, pointing to a recent Ebola outbreak that took two years to end. Nearly 2,300 people died between 2018 and 2020 in the deadliest outbreak in the DRC to date.

“At the international level, [we are] looking at what candidate vaccines or treatment are available and if any could be of use in this outbreak,” Ancia added.

Australia has seen more than 220 cases of diphtheria so far this year, the biggest outbreak of the disease since national records began in 1991.

The Northern Territory has the largest number of positive cases at 133, followed by 82 in Western Australia, six in South Australia, and fewer than five in Queensland.

In response to the outbreak, the federal and state governments have mobilized, and the Commonwealth is preparing a support package to bolster vaccination rates for a disease once considered almost eradicated, ABC News reported.

Authorities are also waiting on the outcome of an investigation into a reported diphtheria-related death in the NT, which would be the first death from the disease in almost a decade.

Federal health minister Mark Butler said the numbers were “very concerning.”

“To put that in context, we've been recording case numbers nationally for about 35 years, and this, by a very big distance, is the biggest outbreak of diphtheria we've ever seen,” he said.

The cases are rising amid falling vaccination rates on the continent.

“I want to say this is not just very serious in terms of its numbers, but the vast majority of new cases we're seeing are respiratory diphtheria, which is far more serious in terms of its potential — about 25 per cent of cases are being hospitalized,” Butler said at a press conference on the NSW Central Coast.

Also read: US Doctor With Ebola Admitted To Hospital In Germany

2 Different Diphtheria Strains Identified

Two strains of diphtheria have been identified in Australia: respiratory and cutaneous. While respiratory diphtheria can affect the nose, throat, and airways, cutaneous affects the skin, causing pus-filled blisters on the skin or large ulcers surrounded by red, sore-looking skin.

The respiratory strain also spreads through droplets from coughing or sneezing, or direct contact with infected wounds.

Even with treatment, one in 10 people with respiratory symptoms die, according to the Australian CDC.

What Is Diphtheria?

As per the World Health Organization (WHO), diphtheria is a disease caused by the Corynebacterium diphtheriae bacterium that affects the upper respiratory tract and, less often, the skin. It also produces a toxin that damages the heart and the nerves. While it is a vaccine-preventable disease, multiple doses are needed to produce and sustain immunity.

Diphtheria has remained a leading cause of childhood death globally. But vaccination has long prevented mortality among children.

Those who are not immunized remain at risk. WHO also mentions that diphtheria can be fatal in 30 per cent of cases, with young children at higher risk of dying if they are unvaccinated and are not receiving proper treatment.

In 2023, an estimated 84 per cent of children worldwide received the recommended 3 doses of diphtheria-containing vaccine during infancy, leaving 16 per cent with no or incomplete coverage.

According to Australia’s Department of Health and Aged Care, between 1926 and 1935, more than 4,000 Australians died from diphtheria.

Vaccination started in Australia in the 1930s, and the disease has rarely been seen since the 1950s. But vaccine coverage has waned since the COVID pandemic, leading to a rising number of cases.

Diphtheria: Signs And Symptoms

Read More: UK Scientists Begin Drug Trial To Mend Broken Heart Syndrome

Within 2 to 5 days after exposure to the bacteria. The symptoms include

• a sore throat,
• fever,
• swollen neck glands,
• weakness.

Diphtheria: How the Disease Is Treated

It is usually treated with diphtheria antitoxin as well as antibiotics. Antitoxin neutralizes the circulating toxin in the blood. Antibiotics stop bacterial replication and thereby toxin production, speed up getting rid of the bacteria, and prevent transmission to others.

How To Prevent Diphtheria

Diphtheria can be prevented by vaccines and routine immunization. The vaccine is given most often combined with vaccines for diseases such as tetanus, pertussis, Hemophilus influenzae, hepatitis B, and inactivated polio.